Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs